Oppenheimer Reiterates Outperform on Voyager Therapeutics, Maintains $16 Price Target
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Jay Olson has reiterated his 'Outperform' rating on Voyager Therapeutics (NASDAQ:VYGR) and maintained a $16 price target.
August 07, 2023 | 2:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst has reiterated an 'Outperform' rating on Voyager Therapeutics and maintained a $16 price target.
The reiteration of an 'Outperform' rating by a reputable analyst like Jay Olson from Oppenheimer is a positive signal for Voyager Therapeutics. The maintained price target of $16 also indicates confidence in the company's performance. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100